Table 2.
Characteristics of the chronic liver disease patients with malignancies:
| A. Patients with hepatocellular carcinoma (HCC) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Pat # | diagnosis |
LDH (U/l) [80-240] |
CRP (mg/l) [<5] |
WBC (G/l) [4.3-10] |
AFP (μg/l) [<15] |
CEA (μg/l) [<5] |
CA19-9 (kU/l) [<37] |
YB-1/p18 |
| 9 | primary | 111 | 5 | 7.2 | 623 ++ | 2 | 2 | pos. ++ |
| 15 | HCV | 525 ++ | 17 ++ | 4.1 | 4 | 2 | 276 ++ | neg. |
| 16 | HCV | 230 | 5 | 6.2 | 1023 ++ | 1 | 10 | neg. |
| 17 | HCV | 162 | 5 | 2.8 | 87 ++ | 2 | 59 ++ | neg. |
| 27 | primary | 179 | 5 | 6.6 | 12598 ++ | 4 | 49 ++ | neg. |
| 38 | HCV | 211 | 5 | 5.1 | 9 | 3 | 36 | neg. |
| 49 | HCV | 254 ++ | 5 | 3.7 | 6 | 3 | 100 ++ | neg. |
| 51 | primary | 136 | 5 | 4.1 | 4 | 1 | 17 | neg. |
| 59 | alcohol | 194 | 9 ++ | 5.3 | 1 | 1 | 16 | pos. ++ |
| 66 | alcohol | 182 | 5 | 3.8 | 155 ++ | 3 | 50 ++ | neg. |
| 74 | HCV | 187 | 5 | 4.0 | 15 | 2 | 30 | neg. |
| 76 | alcohol | 235 | 11 ++ | 4.3 | 208 ++ | 1 | 14 | neg. |
| 86 | HCV | 184 | 5 | 3.4 | 6 | 1 | 34 | pos. ++ |
| 88 | unknown | 175 | 7 ++ | 7.2 | 4 | 2 | 16 | neg. |
| 107 | HCV | 548 ++ | 5 | 5.7 | 10 | 1 | 28 | neg. |
| B. Patients with malignancies other than HCC | ||||||||
| Pat # | diagnosis |
LDH (U/l) [80-240] |
CRP (mg/l) [<5] |
WBC (G/l) [4.3-10] |
AFP (μg/l) [<15] |
CEA (μg/l) [<5] |
CA19-9 (kU/l) [<37] |
YB-1/p18 |
| 41 | PNET | 288 ++ | 31 ++ | 9.7 | 5 | 1 | 363 ++ | neg. |
| 50 | PNET | 121 | 5 | 7.2 | 5 | 1 | 8 | pos. ++ |
| 53 | CCC | 206 | 7 ++ | 5.8 | 9 | 4 | 177 ++ | pos. ++ |
| 77 | PNET | 97 | 6 ++ | 4.4 | 3 | 1 | 84 ++ | pos. ++ |
| 90 | NHL * | 234 | 5 | 2.7 | 40 ++ | 4 | 257 ++ | neg. |
HCV, Hepatitis C virus infection; PNET, pancreatic neuroendocrine tumor; CCC, cholangiocellular carcinoma; NHL, non-hodgkin lymphoma.
*Patient received prior curative radiotherapy.